Accessibility Menu
Arrow-Thin-Down
S&P 500
6,734.11
-0.1%
-3.38
Arrow-Thin-Down
DJI
47,147.48
-0.7%
-309.74
Arrow-Thin-Down
NASDAQ
22,900.59
+0.1%
+30.23
Arrow-Thin-Down
Bitcoin
$94,595.00
-1.7%
-$1,598.04
Arrow-Thin-Down
AAPL
$272.17
-0.3%
-$0.78
Arrow-Thin-Down
AMZN
$234.69
-1.2%
-$2.89
Arrow-Thin-Down
GOOG
$276.69
-0.9%
-$2.43
Arrow-Thin-Down
META
$609.46
-0.1%
-$0.43
Arrow-Thin-Down
MSFT
$509.78
+1.3%
+$6.49
Arrow-Thin-Down
NVDA
$190.17
+1.8%
+$3.31
Arrow-Thin-Down
TSLA
$404.30
+0.6%
+$2.31
Daily Stock GainersDaily Stock LosersMost Active Stocks

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

By Motley Fool YouTube – Jul 2, 2025 at 7:00PM

Explore the exciting world of Kiniksa Pharmaceuticals (KNSA +0.07%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of May 28, 2025. The video was published on Jul. 2, 2025.

Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kiniksa Pharmaceuticals International, Plc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services